dm+d

Unassigned

New Medicines

Type 2 diabetes mellitus in combination with other treatments for type 2 diabetes

Information

New molecular entity
Eli Lilly
Eli Lilly

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Dual glucose-dependent insulinotropic peptide (GIP) and GLP-1 receptor agonist (first in class)
Currently 3.8 million people in the UK are diagnosed with diabetes (90% type 2), and it is estimated that a further 1 million people with type 2 diabetes have not yet been diagnosed [6].
Type 2 diabetes mellitus in combination with other treatments for type 2 diabetes
Subcutaneous injection

Further information

Yes
To be confirmed

Evidence based evaluations

Information

Licence extension / variation
Eli Lilly
Eli Lilly

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Dual glucose-dependent insulinotropic peptide (GIP) and GLP-1 receptor agonist (first in class)
From 2012 figures, 24% of men and 25% of women are obese. A further 42% of men and 32% of women were overweight. This means most adults in England are overweight or obese [1]. The Health Survey for England 2019 found that the percentage of people who are obese had increased to around 27% of men and 29% of women [3].
Obesity or overweight in adults with weight related comorbidities, with or without type 2 diabetes
Subcutaneous injection